Date: 2016-08-09
Type of information: Financing round
Company: Y-mAbs Therapeutics (USA - NY)
Investors:
Amount: $ 25 million
Funding type: seed financing round
Planned used:
Others: * On August 9, 2016, Y-mAbs Therapeutics, an immunotherapy company discovering and developing innovative treatments for patients with cancer, announced that it has raised an additional $15 million in an expansion of its seed round. Fundraising took place with a syndicate mainly consisting of existing shareholders and no placement agent was engaged in connection with the financing. * On January 8, 2016, Y-mAbs Therapeutics announced that it has raised $10 million in a seed round with a syndicate of qualified investors. No placement agent was engaged in connection with the financing. YmAbs Founder, President and Head of Business Development and Strategy, Thomas Gad said, "YmAbs’ story continues to be very well received among investors as our intriguing data gets out there. The funds will further strengthen our strategic pathway to regulatory approval of our leading compounds.” Dr. Claus Møller, Chief Executive Officer further notes, "We are excited to receive this seed funding, which allows us to advance our clinical and regulatory activities and upscale the manufacturing of the lead compounds."
Therapeutic area: Cancer - Oncology
